Intech Investment Management LLC Purchases 29,167 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Intech Investment Management LLC boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 224.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,156 shares of the company’s stock after acquiring an additional 29,167 shares during the quarter. Intech Investment Management LLC owned 0.09% of Amphastar Pharmaceuticals worth $1,565,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its position in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after acquiring an additional 871 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares in the last quarter. KBC Group NV raised its position in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after acquiring an additional 650 shares in the last quarter. Finally, Point72 DIFC Ltd raised its position in shares of Amphastar Pharmaceuticals by 85.9% in the third quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock valued at $192,000 after purchasing an additional 1,827 shares during the period. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 1.4 %

AMPH stock opened at $28.29 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company’s 50-day simple moving average is $31.91 and its 200 day simple moving average is $40.57. Amphastar Pharmaceuticals, Inc. has a 52 week low of $25.89 and a 52 week high of $53.96. The company has a market capitalization of $1.35 billion, a PE ratio of 9.43, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 27.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.